Status:
COMPLETED
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Lead Sponsor:
Bayer
Collaborating Sponsors:
Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called I-Neb. In these patients, the non compliance of the treatment becomes its ineffective and increases the complic...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male or female patients \> 18 years of age.
- Patients in New York Heart Association (NYHA) functional class II-IV pulmonary hypertension who are treated with Ventavis at least three months before and who use -neb ® AAD ® system.
- Patients who accepted participation in the study and sign informed consent.
- Patients with ability to understand and follow the instructions and are able to participate for the duration of the study.
- exclusion Criteria:
- Patients with severe cognitive impairment.
- Geographically unstable patients who can not be followed during the 12 month study.
- Patients who have a life expectancy of at least 12 months.
- Patients who are participating in another study at the time of inclusion. .
Exclusion
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT01468545
Start Date
October 1 2011
End Date
June 1 2014
Last Update
August 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Spain